Sanofi-Aventis recalls a batch of Micropakine

One batch of Micropakine, a medicine prescribed to prevent epilepsy by Sanofi-Aventis, is being recalled due to risk of overdose. The National Agency for the Safety of Medicines and Health Products (ANSM) indicates that batch n ° DM0059 of Micropakine LP 500mg, the expiry date of which is March 2022, has dosage defects. Patients have discovered empty sachets and sachets twice overfilled with sodium valproate granules in two 30-dose boxes. Or the equivalent of Micropakine LP 1000 mg. Overdose of sodium valproate carries a risk of drowsiness and lethargy. The patients concerned must return the boxes to their pharmacy as soon as possible for a free exchange, so as not to interrupt their treatment. If the patient cannot get to the pharmacy, they should contact their pharmacist or attending physician. Sanofi-Aventis France has also asked dispensing pharmacists and pharmacies in healthcare establishments to contact, “ by all means at their disposal », Patients likely to have and / or to have used the specialty of the batch concerned by this recall. ” To date, no case of adverse reaction related to this defect has been reported. », Reassures the ANSM.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.